{"analyses":[{"ciLowerLimit":"0.91","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.89","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.1324","pValueComment":"Not type I error controlled.","paramType":"Hazard Ratio (HR)","paramValue":"1.31","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"76.1","upperLimit":"77.4","value":"76.4"},{"comment":"Upper limit of 95% CI was not estimable due to an insufficient number of participants with events.","groupId":"OG001","lowerLimit":"76.3","upperLimit":"NA","value":"80.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"135"},{"groupId":"OG001","value":"136"}],"units":"Participants"}],"description":"CRR was defined as an achievement of all the following criteria: UPCR \\<0.5 g/g; eGFR \\>=85% of baseline, as calculated using the CKD-EPI equation and no occurrence of intercurrent events of rescue therapy, treatment failure, death or early study withdrawal. Participants who experienced the intercurrent events before achieving CRR as well as participants who completed 76-week treatment period without experiencing CRR were censored at Week 76. Summary statistics of time to onset of CRR are Kaplan-Meier estimates. A log-rank test was used to compare obinutuzumab and placebo. The median time to onset of CRR was greater than Week 76 due to considering the upper limit of the Week 76 analysis visit window in this analysis. The upper limit of the Week 76 visit window was 3 days prior to the next obinutuzumab or placebo infusion or 30 days beyond Week 76 whichever is shorter.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received obinutuzumab, 1000 mg as an IV infusion on Day 1 and Weeks 2, 24, 26, and either Weeks 50 and 52 or Week 52 only, along with MMF and SOC therapy. Placebo was administered at Week 50 for participants not treated with obinutuzumab. Participants with adequate response at Week 76 continued to receive obinutuzumab at Week 80 and Q6M thereafter. The dose of MMF can be adjusted at the investigator's discretion beginning at Week 80.","id":"OG000","title":"Obinutuzumab"},{"description":"Participants received Obinutuzumab matching placebo as an IV infusion on Day 1 and Weeks 2, 24, 26, 50, and 52. Participants also received SOC therapy and MMF. Participants with adequate response at Week 76 continued to receive placebo at Week 80 and Q6M thereafter.","id":"OG001","title":"Placebo"}],"paramType":"MEDIAN","populationDescription":"Efficacy population included all randomized participants regardless of whether they received study drug. As pre-specified in the SAP, all the endpoints were to be compared between the obinutuzumab (combined treatment groups) and placebo groups.","reportingStatus":"POSTED","timeFrame":"From baseline (Day 1) up to 80.3 weeks","title":"Time to Onset of CRR","type":"SECONDARY","unitOfMeasure":"weeks"}